RADIOTHERAPY GRANT

AlphaMed Inc. announced that it received a $500,000 two-year STTR Phase II grant award from the National Cancer Institute to further develop a targeted radiotherapy for metastatic melanoma.

Related Videos
Related Content

Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

March 23rd 2023

New Technology Could Allow Us to Rethink Alopecia Scores

March 23rd 2023

Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

March 23rd 2023

New Technology Could Allow Us to Rethink Alopecia Scores

March 23rd 2023

Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

March 23rd 2023

New Technology Could Allow Us to Rethink Alopecia Scores

March 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.